# Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season

> **NCT00316264** · PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 260 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections
- Chronic Lung Disease and <= 24 Months of Age or
- Premature With Gestational Age <=35 Weeks and <=6 Months of Age

## Interventions

- **BIOLOGICAL:** Motavizumab, palivizumab
- **BIOLOGICAL:** Palivizumab, motavizumab
- **BIOLOGICAL:** Motavizumab

## Key facts

- **NCT ID:** NCT00316264
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2012-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00316264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00316264, "Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00316264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*